Dec. 19, 2008-The European Medicines Agency has been formally notified by Gendux Molecular Limited of its decision to withdraw its application for a centralised marketing authorisation for the medicinal product Advexin (contusugene ladenovec) suspension for injection.
The details can be read here.
No comments:
Post a Comment